Medication adherence analysis for semaglutide once-weekly injection in T2D patients reveals real-world compliance patterns, predictors of adherence, and discontinuation reasons.
Key findingMedication adherence analysis for semaglutide once-weekly injection in T2D patients reveals real-wor
What the researchers found
Medication adherence analysis for semaglutide once-weekly injection in T2D patients reveals real-world compliance patterns, predictors of adherence, and discontinuation reasons.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Cross-sectional study of semaglutide users at an outpatient pharmacy in Tabuk, Saudi Arabia, measuring first-year discontinuation and adherence.
How the study worked
In publication.
Who was studied
Type 2 diabetes patients refilling semaglutide prescriptions at an outpatient pharmacy in Tabuk, Saudi Arabia
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Medication Adherence to Semaglutide Once-Weekly Injection Among Type-2 Diabetes Patients in Tabuk, Saudi Arabia - A Cross-Sectional Study.
Patient preference and adherence, 19, 2535-2551
Citation
Amirthalingam, Palanisamy; Alatawi, Olayan Salamah; Hamdan, Ahmed Mohsen Elsaid; Aljabri, Ahmed; Alqifari, Saleh; Alshareef, Hanan; Hakami, Faris Ahmed M; Albalawi, Nader Salem; A Albrahimi, Hazem Moufeed; Mubark Alanazi, Sultan Mohammed; Alatawi, Ahmed Mutair; Albalwi, Abdullah Abdalziz S; Ali, Mostafa A Sayed. (2025). Medication Adherence to Semaglutide Once-Weekly Injection Among Type-2 Diabetes Patients in Tabuk, Saudi Arabia - A Cross-Sectional Study.. Patient preference and adherence, 19, 2535-2551. https://doi.org/10.2147/PPA.S534534